Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38135816)

  • 21. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
    Lu J; Li X; Li H
    Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative Magnetic Resonance Imaging Radiomics for Predicting Early Recurrence of Glioblastoma.
    Wang J; Yi X; Fu Y; Pang P; Deng H; Tang H; Han Z; Li H; Nie J; Gong G; Hu Z; Tan Z; Chen BT
    Front Oncol; 2021; 11():769188. PubMed ID: 34778086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical evaluation of cystic features in patients with newly diagnosed glioblastoma with IDH-wildtype.
    Kim MJ; Park JS; Jeun SS; Ahn S
    Clin Neurol Neurosurg; 2023 May; 228():107708. PubMed ID: 37043844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative susceptibility mapping evaluation of glioma.
    Zeng S; Ma H; Xie D; Huang Y; Wang M; Zeng W; Zhu N; Ma Z; Yang Z; Chu J; Zhao J
    Eur Radiol; 2023 Oct; 33(10):6636-6647. PubMed ID: 37095360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma.
    Verduin M; Primakov S; Compter I; Woodruff HC; van Kuijk SMJ; Ramaekers BLT; te Dorsthorst M; Revenich EGM; ter Laan M; Pegge SAH; Meijer FJA; Beckervordersandforth J; Speel EJ; Kusters B; de Leng WWJ; Anten MM; Broen MPG; Ackermans L; Schijns OEMG; Teernstra O; Hovinga K; Vooijs MA; Tjan-Heijnen VCG; Eekers DBP; Postma AA; Lambin P; Hoeben A
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.
    Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F
    Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An initial study on the predictive value using multiple MRI characteristics for Ki-67 labeling index in glioma.
    Du N; Shu W; Li K; Deng Y; Xu X; Ye Y; Tang F; Mao R; Lin G; Li S; Fang X
    J Transl Med; 2023 Feb; 21(1):119. PubMed ID: 36774480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular architecture mapping for early detection of glioblastoma recurrence.
    Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
    Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
    Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
    Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
    Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
    Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastomas with and without peritumoral fluid-attenuated inversion recovery (FLAIR) hyperintensity present morphological and microstructural differences on conventional MR images.
    Han Q; Lu Y; Wang D; Li X; Ruan Z; Mei N; Ji X; Geng D; Yin B
    Eur Radiol; 2023 Dec; 33(12):9139-9151. PubMed ID: 37495706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification.
    Dolen D; Ahmadov T; Dolas I; Unal TC; Aydoseli A; Ozturk M; Sabanci PA; Aras Y; Bilgic MB; Sencer A
    Turk Neurosurg; 2022; 32(3):500-507. PubMed ID: 35615769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features.
    Mei N; Lu Y; Yang S; Jiang S; Ruan Z; Wang D; Liu X; Ying Y; Li X; Yin B
    J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):650-658. PubMed ID: 37380154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying overall survival in 98 glioblastomas using VASARI features at 3T.
    Sacli-Bilmez B; Firat Z; Topcuoglu OM; Yaltirik K; Ture U; Ozturk-Isik E
    Clin Imaging; 2023 Jan; 93():86-92. PubMed ID: 36417792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
    Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
    Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.